UNSPSC 51182429: Strontium ranelate

This classification denotes a bone resorption inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04NQ160FRU. European Medicines Agency schedules Strontium ranelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20045. Strontium ranelate generally arises in the molecular formula C12H6N2O8S.2SR. The term 'strontium ranelate' is a European Medicines Agency European Public Assessment Report System designation. As of Q4 2014, STRONTIUM RANELATE remains the US FDA Preferred Term for this commodity.

Strontium ranelate bears US NLM identifiers UMLS ID C0936139 and NCI Concept Code C93265. SMILES: [Sr].[Sr].s1c(N(CC(=O)O)CC(=O)O)c(c(c1C(=O)O)CC(=O)O)C#N.

UNSPSC 51182429 Strontium ranelate is a Commodity code covering a specific pharmaceutical compound used in the treatment of osteoporosis. State and local governments procure strontium ranelate primarily through their health departments, Medicaid agencies, and public health systems to supply to patients requiring bone-density management. The product appears in procurement when public hospitals, clinics, and state-administered healthcare programs stock prescription medications for covered beneficiaries.

The source provides no recent state and local contract opportunities tagged to this code. Without visibility into active solicitations, issuing-body patterns, or geographic concentration, pursuit decisions should focus on direct outreach to state Medicaid pharmacy programs, state health department procurement offices, and county health systems in your target markets rather than on posted opportunity flow.